Kyntra Bio (KYNB) Total Current Liabilities (2014 - 2026)

Kyntra Bio has disclosed Total Current Liabilities across 13 years of filings, most recently posting $36.0 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 76.88% year-over-year to $36.0 million; the TTM figure through Jun 2026 stood at $36.0 million (down 76.88% YoY), while the FY2025 annual figure was $29.2 million, down 78.06% from the prior year.
• Total Current Liabilities came in at $36.0 million for Q2 2026 at Kyntra Bio, up from $28.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $273.6 million in Q4 2022 to a low of $28.1 million in Q1 2026.
• Average Total Current Liabilities over 5 years is $162.5 million, with a median of $192.3 million recorded in 2023.
• Year-over-year, Total Current Liabilities jumped 52.88% in 2022 and plunged 81.12% in 2025.
• Over 5 years, Total Current Liabilities stood at $273.6 million in 2022, then dropped by 20.43% to $217.7 million in 2023, then tumbled by 38.76% to $133.3 million in 2024, then slumped by 78.06% to $29.2 million in 2025, then gained by 23.25% to $36.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $36.0 million in Q2 2026, $28.1 million in Q1 2026, and $29.2 million in Q4 2025.